

## SUPPLEMENTAL MATERIAL

### Expanded Methods

#### Supplemental Table I


Real-time quantitative qPCR was performed with the following primers:

Mouse Primers		
Gene	Forward	Reverse
<i>Acta2</i>	ATCGTCCACCGCAAATGC	AAGGAACTGGAGGCGCTG
<i>Col1a1</i>	GCTCCTCTTAGGGGCCACT	CCACGTCTCACCATTGGGG
<i>Cnn1</i>	AACTTCATGGATGGCCTCAAA	ACCCGGCTGCAGCTTGT
<i>Fbn1</i>	GGAATGACATCAGCAGGCAC	TACACAAATCCTTTGGGGCA
<i>Hif1a</i>	AGCTTCTGTTATGAGGTCAGC	TGACTTGATGTTTCATCGTCC
<i>Mmp2</i>	CAAGTTCCCCGGCGATGTC	TTCTGGTCAAGGTCACCTGTC
<i>Mmp9</i>	CACCACAGCCAACCTATGACCA	CAGGAAGACGAAGGGGAAGAC
<i>Myh11</i>	TCAACGCCAACCGCAGGAAGCTG	TGCTAAGCAGTCTGCTGGGCT
<i>mt-Co1</i>	CTCGCCTAATTTATTCCACTTCA	GGGGCTAGGGGTAGGGTTAT
<i>mt-Nd1</i>	CTAGCAGAAACAAACCGGGC	CCGGCTGCGTATTCTACGTT
<i>Nos2</i>	CTTTGCCACGGACGAGAC	TCATTGTACTCTGAGGGCTGAC
<i>Smtn</i>	TCACTACCTTCAGCCATGCCT	GCCATTAGCTGCTTCCACTGT
<i>Spp1</i>	ATGAGATTGGCAGTGATTTG	CATCCTTTTCTTCAGAGGAC
<i>Tagln</i>	CTATGAAGGTAAGGATATGGC	TCTGTGAAGTCCCTCTTATG
<i>Tfam</i>	CAGGAGGCAAAGGATGATTC	CCAAGACTTCATTTTCATTGTCG
<i>Ppargc1a</i>	GGCACGCAGCCCTATTCA	CGACACGGAGAGTTAAAGGAAGA
<b>At least two different reference targets among these were used for normalization:</b>		
<i>b2m</i>	TACATACGCCTGCAGAGTTAAGCA	TGATCACATGTCTCGATCCCAG)
<i>pp1a</i>	ACGCCACTGTGCTTTTC	GCAAACAGCTCGAAGGAGAC
<i>Ywhaz</i>	TACTTGGCCGAGGTTGCT	TGCTGTGACTGGTCCACAAT
<i>Bactin</i>	CTAAGGCCAACCGTGAAAAG	ACCAGAGGCATACAGGGACA
<b>for mtDNA</b>		
<i>mt-Co1</i>	CTCGCCTAATTTATTCCACTTCA	GGGGCTAGGGGTAGGGTTAT
<i>mt-Nd1</i>	CTAGCAGAAACAAACCGGGC	CCGGCTGCGTATTCTACGTT
<i>16s Mt-rRNA</i>	CCGCAAGGGAAAGATGAAAGAC	TCGTTTGGTTTCGGGGTTTC
<b>For nDNA</b>		
<i>Hk2</i>	GCCAGCCTCTCCTGATTTAGTGT	GGGAACACAAAAGACCTCTTCTGG

Human primers		
Gene	Forward	Reverse
<i>ACAN</i>	TCGAGGACAGCGAGGCC	TCGAGGGTGTAGCGTGTAGAGA
<i>CCN2</i>	CGACTGGAAGACACGTTTGG	AGGCTTGGAGATTTTGGGAG
<i>COL1A1</i>	ATGTCTAGGGTCTAGACATGTTCA	CCTTGCCGTTGTGCGAGACG
<i>CYCS</i>	-GCCTGCCTGATCCTCAAAT	AAGGTAGCGGATGATTCAGCC-
<i>HIF1A</i>	GTGGATTACCACAGCTGA	GCTCAGTAACTTGATCCA
<i>MMP2</i>	CTCAGATCCGTGGTGAGATCT	CTTTGGTTCTCCAGCTTCAGG


<i>MMP9</i>	ATCCAGTTTGGTGTGCGGGAGC	GAAGGGGAAGACGCACAGCT
<i>MYC</i>	AAACACAAACTTGAACAGCTAC	ATTTGAGGCAGTTTACATTATGG
<i>MT-ATP6</i>	TAGCCATACACAACACTAAAGGACGA	GGGCATTTTTAATCTTAGAGCGAAA
<i>MT-COI</i>	GACGTAGACACACGAGCATATTTCA	AGGACATAGTGGAAGTGAGCTACAAC
<i>MT-ND1</i>	CCACCTCTAGCCTAGCCGTTTA	GGGTCATGATGGCAGGAGTAAT
<i>PPARA</i>	CTATCATTTGCTGTGGAGATCG	AAGATATCGTCCGGGTGGTT
<i>PPARG</i>	GAGAAGGAGAAGCTGTTGGC	ATGGCCACCTCTTTGCTCT
<i>PPARGC1A</i>	GGCAGAAGGCAATTGAAGAG	TCAAAACGGTCCCTCAGTTC
<i>SDHA</i>	TGGGAACAAGAGGGCATCTG	CCACCACTGCATCAAATTCATG
<i>SDHB</i>	GACACCAACCTCAATAAG	GATTCATCCTTCTTCTTCAA
<i>TGFB3</i>	TGAGTGGCTGTTGAGAAGAGA	ATTGTCCACGCCTTTGAATTTGAT
<i>TFAM</i>	CCGAGGTGGTTTTTCATCTGT	GCATCTGGGTTCTGAGCTTT
<b>At least two different reference targets among these were used for normalization:</b>		
<i>UBC</i>	ATTTGGGTCGCGGTTCTTG	TGCCTTGACATTCTCGATGG
<i>GADPH</i>	GAAGGTGAAGGTCGGAGTC	GAAGATGGTGATGGGATTC
<i>BACTIN</i>	GATCATTGCTCCTCCTGAGC	ACATCTGCTGGAAGGTGGAC
<b>mtDNA</b>		
<i>CYCS</i>	GCCTGCCTGATCCTCCAAAT	AAGGTAGCGGATGATTCAGCC-
<i>MT-COI</i>	CCACCTCTAGCCTAGCCGTTTA	GGGTCATGATGGCAGGAGTAAT
16s MT-LEU-tRNA	CACCCAAGAACAGGGTTTGT	TGGCCATGGGTATGTTGTTA
<b>nDNA</b>		
<i>B2M</i>	TGCTGTCTCCATGTTTGATGTATCT	TCTCTGCTCCCCACCTCTAAGT

## Supplemental Figures and Figure Legends




### Supplemental Figure I: Senescent and inflammatory phenotype in *Fbn1*-deficient VSMCs.

Primary VSMCs were transduced with *shFbn1* as *in vitro* model of MFS. (A) RT-qPCR analysis of *Fbn1*. (B) RT-qPCR (n=6) and representative immunoblot (out of 4) analysis of *p53* (n=4). (C) Relative senescent associated B-galactosidase activity. (D) RT-qPCR analysis of pro-inflammatory genes *Tnfa*, *Il1b* and *Il6*. Data are mean  $\pm$  s.e.m. Statistical significance was assessed by Student's t-test \*P < 0.05, \*\*P < 0.01 vs *shControl*.




**Supplemental Figure II: Immunofluorescence analysis of metabolic proteins in human aortic media from MFS patients.**

Representative medial layer sections from ascending aortas of control donors and MFS patients, showing immunofluorescence confocal analysis for MT-CO1 (CoIV), SDHA (CoII), TFAM HIF1A, and MYC (white); SMA (red), and elastin (green autofluorescence).




**Supplemental Figure III: Gene expression profile at different ages in *Fbn1*<sup>C1039G/+</sup> mice**

RT-qPCR analysis of indicated genes in aortas from *Fbn1*<sup>+/+</sup> and *Fbn1*<sup>C1039G/+</sup> mice at different ages. Statistical significance was assessed by Student's t-test \*P < 0.05, \*\*P < 0.01, \*\*\*P < 0.001 vs *Fbn1*<sup>+/+</sup>.




**Supplemental Figure IV: Senescent and inflammatory phenotype in *Tfam*-deficient VSMCs.**

(A-B) Primary mouse *Tfam*<sup>flox/flox</sup> VSMCs were transduced with GFP-expressing (LV-Mock) or Cre-expressing (LV-Cre) lentivectors and analyzed after fourteen days. (A) RT-qPCR analysis of relative *Tp53*, and *Cdkn1a* and representative immunoblot of P53. Actin was used as total protein loading control. (B) RT-qPCR analysis of relative *Il6*, and *Tnfa*. (C) *SM-Tfam*<sup>+/+</sup> and *SM-Tfam*<sup>-/-</sup> mice were treated with Tmx at five weeks of age. (C) RT-qPCR analysis of the indicated genes in aortic extracts twelve weeks after Tmx. Statistical significance was assessed by Student's t-test \*P < 0.05, \*\*P < 0.01, \*\*\*P < 0.001 vs Lv-Mock (A,B) or *SM-Tfam*<sup>+/+</sup>.



### Supplemental Figure V: NR treatment reverts aortic dilation in female MFS mice

(A) Experimental design: 16-week-old *Fbn1*<sup>+/+</sup> and *Fbn1*<sup>C1039G/+</sup> female mice were treated with vehicle or NR for 28 days as follows: n=4 *Fbn1*<sup>+/+</sup> mice; n=3 vehicle-treated *Fbn1*<sup>C1039G/+</sup> mice; n=3 NR-treated *Fbn1*<sup>C1039G/+</sup> mice. Ultrasound and BP analysis was performed five times (empty triangles). (B) Maximal AsAo and AbAo diameters and systolic and diastolic BP after NR treatment. (C) Quantification of AsAo elastin breaks and aortic medial thickness. Statistical significance was assessed by two-way repeated measurements ANOVA (B) or one-way ANOVA (C). \*P < 0.05, \*\*P < 0.01, vs *Fbn1*<sup>+/+</sup>; # P < 0.05, ###P < 0.001, for *Fbn1*<sup>C1039G/+</sup> vs *Fbn1*<sup>C1039G/+</sup> NR.



**Supplemental Figure VI: Proposed model depicting the critical role of mitochondrial decline in promoting aortic alterations in Marfan syndrome.**

Marfan syndrome (MFS) is an autosomal dominant disorder caused by mutations in the extracellular protein FBN1. The major complication of MFS is the development of thoracic aortic aneurysms, which are characterized by aortic dilation and extracellular matrix (ECM) remodeling. ECM from MFS cells modulates VSMC metabolism promoting a switch from mitochondrial respiration to glycolysis. Glycolytic VSMCs acquire a senescent and inflammatory phenotype with decreased contractile capacity favoring the development of the aneurysm. Restoring mitochondrial metabolism with the NAD-precursor nicotinamide riboside rapidly reverts aortic aneurysm in *Fbn1*<sup>c1039g/+</sup> mice.